Abcam buys AxioMx for antibody production technology
Abcam has acquired monoclonal antibody production specialist AxioMx in a deal worth up to $45m (€42m).
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Abcam has acquired monoclonal antibody production specialist AxioMx in a deal worth up to $45m (€42m).